|
VHPB Centre for Evaluation of Vaccination (CEV) |
Executive Secretary Administrative and Scientific Secretariat |
privacy statement
|
Posted: December 8, 2013
List of VHPB publications online available
One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. Andani A, van Damme P, Bunge EM, Salgado F, van Hoorn RC, Hoet B. Vaccine. 2022 Jan 21;40(2):196-205. doi: 10.1016/j.vaccine.2021.01.038. Epub 2021 Jan 30. PMID: 33526283.
| Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019). | ||
| Sperle I, Nielsen S, Bremer V, Gassowski M, Brummer-Korvenkontio H, Bruni R, Ciccaglione AR, Kaneva E, Liitsola K, Naneva Z, Parchemlieva T, Spada E, Toikkanen SE, Amato-Gauci AJ, Duffell E, Zimmerman R on behalf of the SPHERE-C Expert Group. | ||
| Front. Public Health, 28 May 2021; doi: 10.3389/fpubh.2021.568524 | ||
| Many European countries 'flying blind' in their efforts to eliminate viral hepatitis. | ||
| Lazarus JV, Safreed-Harmon K, Colombo M, Reic T, Schatz E, Van Damme P; ACHIEVE Coalition. | ||
| Nat Rev Gastroenterol Hepatol. 2017 Jul 26;14(8):445-446. doi: 10.1038/nrgastro.2017.98. | ||
| Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response. | ||
| Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C. | ||
| J Infect Dis. 2016 Nov 15;214(10):1498-1506 | ||
| Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report. | ||
| David FitzSimons, Greet Hendrickx, Johannes Hallauer, Heidi Larson, Daniel Lavanchy, Ina Lodewyckx,Daniel Shouval, John Ward and Pierre Van Damme. | ||
| Hepatology, Medicine and Policy; 2016, 1:16. DOI 10.1186/s41124-016-0022-8 | ||
| Editorial on "What is a potentially damaging vaccination delay in children younger than 2 years?" |
| Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P; Viral Hepatitis Prevention Board. |
| Hum Vaccin Immunother. 2016 Aug 2;12(8):2053-2056. |
| A hepatitis-free future: strategy first, then pricing. | ||
| Heidi Larson, Pierre Van Damme & David FitzSimons | ||
| Lancet Infect Dis & 2016, 16(4):399-400. doi: 10.1016/S1473-3099(16)00126-2. | ||
| Editorial on “What is a potentially damaging vaccination delay in children younger than 2 years?” | ||
| Mark A. Kane, Francois Roudot-Thoraval, Nicole Guerin, Vassiliki Papaevangelou, Pierre Van Damme & on behalf of the Viral Hepatitis Prevention Board | ||
| Human Vaccines & Immunotherapeutics 2016, DOI:10.1080/21645515.2016.1177689 | ||
| Long-term Protection After Hepatitis B Vaccine | ||
| van Damme P | ||
| J Infect Dis. 2016, doi: 10.1093/infdis/jiv750 | ||
| Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria,2010-2011 | ||
| Kevorkyan A1, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. | ||
| J Med Virol 2015,87: 401-406 | ||
| A cohesive European policy for hepatitis B vaccination, are we there yet? | ||
| Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P. | ||
| Clin Microbiol Infect 2014,20 Suppl 5: 19-24 | ||
| Viral Hepatitis Prevention B. Reduced prevalence of HBsAg variants following a successful immunization program in China. | ||
| Jilg W, Norder H, Kane M, Van Damme P, Vorsters A. | ||
| J Virol 2014, 88: 4605-4606 | ||
| Incentives and barriers regarding immunization against influenza and hepatitis of health care workers. | ||
| Meeting report Barcelona | ||
| FitzSimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P. | ||
| Vaccine 2014, 32: 4849-4854 | ||
| Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22 23 March 2012 | ||
| Meeting report | ||
| David FitzSimons, Brian McMahon, Greet Hendrickx, Alex Vorsters, Pierre Van Damme | ||
| Int J Circumpolar Health 2013, 72: 21163 | 99 Kb | |
| Should Europe have a universal hepatitis B vaccination programme? | ||
| Head to head | ||
| Pierre Van Damme, Elke Leuridan, Greet Hendrickx, Alex Vorsters, Heidi Theeten | ||
| BMJ 2013, 347: f4057 | 163 Kb | |
| Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. | ||
| Meeting report Milan | ||
| FitzSimons D, Hendrickx G, Vorsters A, Van Damme P | ||
| Vaccine 2013, 31: 584-590 | ||
| Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery. | ||
| Hendrickx G, Vorsters A, Van Damme P. A. | ||
| Curr Opin Infect Dis 2012, 25: 578-583 | ||
| Identification and management of persons with chronic viral hepatitis in Europe | ||
| Meeting report Budapest | ||
| David FitzSimons, Greet Hendrickx, Alex Vorsters, Pierre Van Damme | ||
| European Gastroenterology & Hepatology Review, vol 8, Iss 1, spring 2012 | 5,6 Mb | |
| Burden and prevention of viral hepatitis in Bulgaria. | ||
| Meeting report Bulgaria | ||
| Fitzsimons D, Kojouharova M, Hallauer J, Hendrickx G, Vorsters A, Van Damme P. | ||
| Vaccine 2011, 29: 8471-8476 | 5,6 Mb | |
| Hepatitis A and E: Update on Prevention and Epidemiology | ||
| Meeting report | ||
| David FitzSimons, Greet Hendrickx, Alex Vorsters, Pierre Van Damme | ||
| Vaccine 2009, 28: 583 - 588 | 121 Kb | |
| The clock is running. | ||
| Vorsters A, Van Herck K, Van Damme P. | ||
| Vaccine 2009, 27: 2905-2906 | 121 Kb | |
| Prevention of viral hepatitis (B and C) reassessed. | ||
| Van Herck K, Vorsters A, Van Damme P. | ||
| Best Pract Res Clin Gastroenterol 2008, 22: 1009-1029 | 121 Kb | |
| Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. | ||
| Meeting report Hepatitis A, Miami 2007 | ||
| Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, et al. | ||
| J Viral Hepat 2008,15 (Suppl 2): 1-15 | 110 Kb | |
| Prevention and control of viral hepatitis: the role and impact of patient and advocacy groups in and outside Europe. | ||
| Meeting report Lucca, Italy 2008 | ||
| FitzSimons DW | ||
| Vaccine 2008, 26: 5669-5674 | 125 Kb | |
| Prevention and control of viral hepatitis through adolescent health programmes in Europe | ||
| Meeting report Ljubljana, Slovenia 2007 | ||
| David FitzSimons, Alex Vorsters, Karel Hoppenbrouwers, Pierre Van Damme | ||
| Vaccine 2007, 25: 8651-865 | 110 Kb | |
| Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. | ||
| Meeting report Rome, Italy 2005 | ||
| FitzSimons D, Francois G, De Carli G, Shouval D, Pruss-Ustun A, Puro V, Williams I, Lavanchy D, De Schryver A, Kopka A, Ncube F, Ippolito G, Van Damme P. | ||
| 143 Kb | ||
| Measurement and reporting of burden of disease for hepatitis A: results of the EUROHEP.NET feasibility survey. | ||
| Report Eurohep.Net project | ||
| Bonanni P, Boccalini S, Bechini A. | ||
| Eur J Public Health 2007, 17:69-74 | 90 Kb | |
| Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. | ||
| Report Sevillia, Spain 2004 | ||
| Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Bocher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV. | ||
| Vaccine 2005, 23: 4158-4166 | 112 Kb | |
| Prevention of viral hepatitis in the Nordic countries and Germany | ||
| Meeting report Berlin, Germany 2003 | ||
| Fitzsimons D, Francois G, Alpers K, Radun D, Hallauer J, Jilg W, Gerlich W, Rombo L, Blystad H, Nokleby H, van Damme P. | ||
| Scand J Infect Dis 2005, 37: 549-560 | ||
| Prevention of viral hepatitis in Italy. | ||
| Report Italy 2004 | ||
| FitzSimons, D., Francois, G., Bonanni, P., Mele, A., Zanetti, A., Stroffolini, T., Crovari, P. and Van Damme, P. | ||
| Vaccine 2004, 22: 4092-4096 | 66 Kb | |
| Combined hepatitis B vaccines. | ||
| Report Malta meeting 2001 | ||
| FitzSimons D, Francois G, Emiroglu N, Van Damme P. | ||
| Vaccine 2003, 21: 1310-1316 | 64 Kb | |
| Hepatitis B vaccination in Britain: time to change ? | ||
| Editorial | ||
| Jangu Banatvala, Pierre Van Damme, Nedret Emiroglu | ||
| BMJ 2006, 332: 804 | 46 Kb | |
| Strengthening immunisation systems and introduction of hepatitis B vaccine in CEE and NIS | ||
| Meeting report | ||
| Alexandra Levitt, Alex Vorsters, Nedret Emiroglu, Susan Goldstein, Tore Godal, Mark Kane, Dragoslav Popovic, Steven Wiersma, Pierre Van Damme | ||
| May 2004 | 1,652 Kb | |
| Strengthening immunisation systems and introduction of hepatitis B vaccine in CEE and NIS | ||
| Meeting report | ||
| David FitzSimons, Pierre Van Damme, Nedret Emiroglu, Tore Godal, Mark Kane, Alexander Malyavin, Harold Margolis, André Meheus | ||
| Vaccine 2002, 20(11-12): 1475-9 | 626 Kb | |
| A Technical Consultation on the Safety of hepatitis B Vaccines | ||
| Meeting report | ||
| Andy Hall, Pierre Van Damme | ||
| Sep 1998 | 218 Kb (.doc) | |
| Prevention and control of hepatitis B in Central and Eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996 | ||
| Meeting report | ||
| David Fitzsimons, Pierre Van Damme | ||
| Oct 1996 | 568 Kb (.doc) | |
List of other VHPB documents available in hard copy
| Vaccine safety controversies and the future of vaccination programs | ||
| Meeting report | ||
| Guido François, Philippe Duclos, Harold Margolis, Daniel Lavanchy, Claire-Anne Siegrist, André Meheus, Paul-Henri Lambert, Nedret Emiroglu, Selim Badur, Pierre Van Damme | ||
| Pediatr Infect Dis J. 2005, 24(11): 953-961 |
 |
|
| Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants | ||
| Meeting report | ||
| David FitzSimons, Guido François, Andy Hall, Brian McMahon, André Meheus, Alessandro Zanetti, Bernard Duval, Wolfgang Jilg, Wulf Böcher, Sheng-Nan Lu, Ulus Akarca, Daniel Lavanchy, Susan Goldstein, Jangu Banatvala, Pierre Van Damme | ||
| Vaccine 2005, 23: 4158-4166 |
|
|
| Prevention of viral hepatitis in the Nordic Countries and Germany | ||
| Meeting report | ||
| David FitzSimons, Guido François, Katharina Alpers, Doris Radun, Johannes Hallauer, Wolfgang Jilg, Wolfram Gerlich, Lars Rombo,, Hans Blystad, Hanne Nokleby, Pierre Van Damme | ||
| Scandinavian Journal of Infectious Diseases 2005, 37 (8): 549-561 |
|
|
| Prevention of hepatitis C virus infection | ||
| Meeting report | ||
| Michael Kew, Guido François, Daniel Lavanchy, Harold Margolis, Pierre Van Damme, Peter Grob, Johannes Hallauer, Daniel Shouval, Geert Leroux-Roels, André Meheus | ||
| Journal of Viral Hepatitis 2004, 11: 198-205 |
|
|
| Prevention of viral hepatitis in Italy | ||
| Meeting report | ||
| David FitzSimons, Guido François, Paolo Bonanni, Alfonso Mele, Alessandro Zanetti, Tommaso Stroffolini, Pietro Crovari, Pierre Van Damme | ||
| Vaccine 2004, 22: 4092-4096 |
|
|
| Combined hepatitis B vaccines | ||
| Meeting report | ||
| David Fitzsimons, Guido François, Nedret Emiroglu, Pierre Van Damme | ||
| Vaccine 2003, 21: 1310-1316 |
|
|
| Economic evalutation of vaccination programmes; a consensus statement focusing on viral hepatitis | ||
| Review | ||
| Philippe Beutels, W. John Edmunds, Fernando Antonanzas, Marc Péchevis, David Evans, Rachel Feilden, A. Mark Fendrick, Gary M. Ginsberg, Henry A. Glick, Eric Mast, G. Ardine De Wit, Eddy Van Doorslaer, Ben A. van Hout | ||
| Pharmacoeconomics 2002: 20 (1): 1-7 |
|
|
| Hepatitis B vaccination: how to reach risk groups | ||
| Meeting report | ||
| Guido François, Johannes Hallauer, Pierre Van Damme | ||
| Vaccine 2002, 21: 1-4 |
|
|
| Strengthening immunisation systems and introduction of hepatitis B vaccine in CEE and NIS | ||
| Meeting report | ||
| David FitzSimons, Pierre Van Damme, Nedret Emiroglu, Tore Godal, Mark Kane, Alexander Malyavin, Harold Margolis, André Meheus | ||
| Vaccine 2002, 20: 1475-1479 |
|
|
| Behavioural Issues in hepatitis B Vaccination | ||
| Meeting report | ||
| Stephen Bartlett, Pierre Van Damme | ||
| Mar 2000 |
|
|
| Multiple Sclerosis and hepatitis B Vaccine? | ||
| Meeting report | ||
| Andy Hall, Mark Kane, André Meheus, Colette Roure | ||
| Vaccine 1999, 17 (20-21): 2473-2475 |
|
|
| Hepatitis B Vaccine and Central Nervous System Demyelinating Diseases | ||
| Meeting report | ||
| Neal Halsey, Philippe Duclos, Pierre Van Damme, Harold Margolis | ||
| Pediatr. Infect. Dis. J. 1999, 18: 23-24 |
|
|
| Control of hepatitis B in Europe: where are we in 1997? | ||
| Meeting report | ||
| Mark Kane, André Meheus, Pierre Van Damme | ||
| Vaccine, 1998, 16 (Suppl.): S1-S110 |
|
|
| Integration of hepatitis B vaccination into national immunisation programmes | ||
| Article | ||
| Pierre Van Damme, Mark Kane, André Meheus | ||
| BMJ 1997, 314: 1033-1037 |
|
|
| Prevention and Control of hepatitis B in Central and Eastern Europe and the Newly Independent States | ||
| Meeting report | ||
| David Fitzsimons, Pierre Van Damme | ||
| Vaccine 1997, 15 (15): 1595-1597 |
|
|
| Prevention and Control of hepatitis B in the Community | ||
| Blue book, Communicable Diseases Series | ||
| P Grosheide, Pierre Van Damme | ||
| Jan 1996 |
|
|
| Proceedings of the International Congress on action towards control of hepatitis B as a community health risk | ||
| Meeting report | ||
| Johannes Hallauer, Wolfgang Jilg, Mark Kane, Pierre Van Damme | ||
| Vaccine 1995, 13 (Suppl. 1): S1-S116 |
|
|
| Hepatitis B as an occupational Hazard | ||
| Yellow book | ||
| European Occupational Health | ||
|
|
||